Objetivo
The aim of this project is to develop a new generation vaccine for schistosomiasis. The vaccine will be based on exposed proteins and/or glycans of the vulnerable skin stage schistosomula, making it safe and effective. The life stage-specific vaccine target selection strategy is based on state-of-the-art schistosomal transcriptomics and glycomics technologies and data, and unique serum and sample libraries from endemic areas will be the key to identifying protective immune responses and effective targets. Preclinical in vitro (cellular and whole parasite) and in vivo (rat model) testing of protective antigens with respect to cellular responses and effective parasite killing are part of the development pipeline. Analysis of human T- and B-cell responsiveness is an integral part of the approach. A unique SME-led approach to potentiate the effect of immunisation by use of engineering engineered antibodies will also be part of the project. The project involves strong participation of researchers from four schistosomiasis-endemic countries, and several European groups all with a long history of successful collaboration.
Ámbito científico
Convocatoria de propuestas
FP7-HEALTH-2009-single-stage
Consulte otros proyectos de esta convocatoria
Régimen de financiación
CP-FP-SICA - Small/medium-scale focused research project for specific cooperation actions dedicated to international cooperation partner countries(SICA)Coordinador
2333 ZA Leiden
Países Bajos
Ver en el mapa
Participantes (12)
59019 Lille
Ver en el mapa
CB2 1TN Cambridge
Ver en el mapa
1165 Kobenhavn
Ver en el mapa
23845 Borstel
Ver en el mapa
SY23 3BF Aberystwyth
Ver en el mapa
82152 Martinsried
Ver en el mapa
13901 Lambarene
Ver en el mapa
N/A LEGON ACCRA
Ver en el mapa
1661 Kampala
Ver en el mapa
00200 Nairobi
Ver en el mapa
75794 Paris
Ver en el mapa
118 Lambaréné
Ver en el mapa